The investment deal also offers MDCO an option to license GeNO’s technologies in the acute and intensive care hospital setting in certain geographies.

The Medicines Company executive vice president Glenn Sblendorio said this equity investment affords MDCO the potential to provide nitric oxide (NO) therapy solutions to healthcare providers in the near future.

NO therapy is used to treat term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.